Edward Gershburg
Overview
Explore the profile of Edward Gershburg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
525
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Plotkin S, Robinson J, Fitchett J, Gershburg E
Clin Infect Dis
. 2024 Sep;
79(6):1518-1520.
PMID: 39240717
Vaccines based on messenger RNA technology have been tremendously successful, but their properties are not necessarily ideal for all pathogens. There is a risk that concentration on that technology alone...
2.
Gmyrek G, Predki P, Gershburg E, Carr D
J Virol
. 2022 Jan;
96(6):e0172421.
PMID: 35045268
Previous studies by our group identified a highly efficacious vaccine 0ΔNLS (deficient in the nuclear localization signal of infected cell protein 0) against herpes simplex virus 1 (HSV-1) in an...
3.
Carr D, Berube A, Gershburg E
Pathogens
. 2021 Nov;
10(11).
PMID: 34832625
Vaccines to viral pathogens in experimental animal models are often deemed successful if immunization enhances resistance of the host to virus challenge as measured by cumulative survival, reduction in virus...
4.
Stanfield B, Kousoulas K, Fernandez A, Gershburg E
Viruses
. 2021 Aug;
13(8).
PMID: 34452501
Diseases caused by human herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) affect millions of people worldwide and range from fatal encephalitis in neonates and herpes keratitis to...
5.
Joyce J, Patel A, Murphy B, Carr D, Gershburg E, Bertke A
Vaccines (Basel)
. 2021 Apr;
9(3).
PMID: 33805768
Treatment to ameliorate the symptoms of infection with herpes simplex virus 2 (HSV-2) and to suppress reactivation has been available for decades. However, a safe and effective preventative or therapeutic...
6.
Goswami R, Shair K, Gershburg E
J Gen Virol
. 2017 Aug;
98(9):2343-2350.
PMID: 28795661
The Epstein-Barr virus (EBV) is a ubiquitous pathogen that infects over 90 % of adults. EBV is the primary etiological agent of infectious mononucleosis and is closely associated with nasopharyngeal...
7.
Gershburg S, Geltz J, Peterson K, Halford W, Gershburg E
PLoS One
. 2015 Jun;
10(6):e0131420.
PMID: 26115119
Herpes simplex virus type 1 (HSV-1) encodes two bona fide serine/threonine protein kinases, the US3 and UL13 gene products. HSV-1 ΔUS3 mutants replicate with wild-type efficiency in cultured cells, and...
8.
Chambers C, Halford W, Geltz J, Villamizar O, Gross J, Embalabala A, et al.
PLoS One
. 2015 Mar;
10(3):e0122253.
PMID: 25823013
Expression systems used to study the biological function of a gene of interest can have limited utility due to three major factors: i) weak or heterogeneous gene expression; ii) poorly...
9.
Geltz J, Gershburg E, Halford W
PLoS One
. 2015 Feb;
10(2):e0116091.
PMID: 25658852
Virion glycoproteins such as glycoprotein D (gD) are believed to be the dominant antigens of herpes simplex virus 2 (HSV-2). We have observed that mice immunized with a live HSV-2...
10.
Halford W, Geltz J, Gershburg E
PLoS One
. 2013 Jun;
8(6):e65523.
PMID: 23755244
We lack a correlate of immunity to herpes simplex virus 2 (HSV-2) that may be used to differentiate whether a HSV-2 vaccine elicits robust or anemic protection against genital herpes....